G2 Investment Partners Management LLC Invests $1.41 Million in Phibro Animal Health Corporation $PAHC

G2 Investment Partners Management LLC bought a new position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 55,000 shares of the company’s stock, valued at approximately $1,405,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Cetera Investment Advisers lifted its stake in Phibro Animal Health by 18.9% in the 1st quarter. Cetera Investment Advisers now owns 11,550 shares of the company’s stock worth $247,000 after purchasing an additional 1,840 shares in the last quarter. LPL Financial LLC grew its position in shares of Phibro Animal Health by 46.8% during the first quarter. LPL Financial LLC now owns 128,335 shares of the company’s stock valued at $2,741,000 after purchasing an additional 40,889 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Phibro Animal Health by 0.4% in the first quarter. Vanguard Group Inc. now owns 1,521,520 shares of the company’s stock worth $32,500,000 after purchasing an additional 6,784 shares during the last quarter. National Bank of Canada FI purchased a new stake in shares of Phibro Animal Health in the first quarter worth about $30,000. Finally, Invesco Ltd. lifted its position in shares of Phibro Animal Health by 92.3% in the first quarter. Invesco Ltd. now owns 387,739 shares of the company’s stock worth $8,282,000 after buying an additional 186,087 shares in the last quarter. 99.34% of the stock is currently owned by institutional investors.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 1,288 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $40.19, for a total transaction of $51,764.72. Following the completion of the transaction, the chief executive officer owned 44,952 shares in the company, valued at $1,806,620.88. The trade was a 2.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 147,824 shares of company stock valued at $6,385,720 over the last ninety days. 50.13% of the stock is owned by company insiders.

Phibro Animal Health Stock Performance

NASDAQ:PAHC opened at $40.15 on Friday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.35 and a current ratio of 3.09. The stock’s fifty day moving average is $41.23 and its 200 day moving average is $34.51. The firm has a market capitalization of $1.63 billion, a PE ratio of 24.19, a PEG ratio of 1.15 and a beta of 0.77. Phibro Animal Health Corporation has a fifty-two week low of $16.16 and a fifty-two week high of $46.42.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15. The business had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, sell-side analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th will be paid a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, November 26th. This represents a $0.48 annualized dividend and a yield of 1.2%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 28.92%.

Analysts Set New Price Targets

PAHC has been the topic of a number of research reports. Morgan Stanley set a $34.00 price objective on Phibro Animal Health in a research note on Thursday, August 28th. Bank of America raised their target price on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a report on Friday, August 29th. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $31.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.